; and (B) publicly posting information about the shortage, the steps the Food and Drug Administration is taking to address the shortage, and an estimated date by which the shortage is expected to be resolved. 3. Expedited consideration of certain abbreviated new drug applications Chapter V of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 351 et seq. ) is amended by inserting after section 506L the following: 506M. Expedited consideration of certain abbreviated new drug applications (a) In general The Secretary may, at the request of a sponsor of an application for an applicable drug, expedite the development and review of an abbreviated new drug application under section 505(j) for such drug. (b) Applicable drug For purposes of this section, an applicable drug is a drug for which there are fewer than 2 drugs approved under section 505(j) that are manufactured domestically, as described in paragraph (2), each of which is approved pursuant to an application under section 505(j) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355(j) ) and references the same listed drug under paragraph (7) of such section 505(j). (c) Actions In expediting the development and review of an application under subsection (a), the Secretary may, as requested by the applicant, take actions including the following: (1) Hold meetings with the applicant and the review team throughout the development of the drug prior to submission of the application for such drug under section 505(j). (2) Provide timely advice to, and interactive communication with, the applicant regarding the development of the drug to ensure that the development program to gather the data necessary for approval is as efficient as practicable. (3) Involve senior managers and experienced review staff, as appropriate, in a collaborative, coordinated review of such application, including with respect to drug-device combination products and other complex products. (4) Assign a cross-disciplinary project lead— (A) to facilitate an efficient review of the